$256 Million is the total value of HARBOURVEST PARTNERS LLC's 26 reported holdings in Q4 2020. The portfolio turnover from Q3 2020 to Q4 2020 was 0.0% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
EVLO | Evelo Biosciences, Inc. | $37,038,000 | +129.4% | 3,063,505 | 0.0% | 14.47% | +142.3% | |
AXLA | Axcella Health, Inc. | $14,573,000 | +12.3% | 2,807,981 | 0.0% | 5.70% | +18.6% | |
TDOC | TelaDoc Health, Inc. | $10,187,000 | -8.8% | 50,943 | 0.0% | 3.98% | -3.7% | |
RUBY | Rubius Therapeutics, Inc. | $7,490,000 | +51.5% | 986,878 | 0.0% | 2.93% | +59.9% | |
LC | LendingClub Corp. | $5,422,000 | +124.2% | 513,440 | 0.0% | 2.12% | +136.8% | |
LOV | Spark Networks SEsponsored adr | $2,674,000 | +8.8% | 502,576 | 0.0% | 1.04% | +14.8% | |
ZUO | Zuora, Inc. | $2,283,000 | +34.7% | 163,894 | 0.0% | 0.89% | +42.3% | |
YEXT | Yext, Inc. | $1,810,000 | +3.5% | 115,147 | 0.0% | 0.71% | +9.3% | |
AR | Antero Resources LLC | $719,000 | +98.1% | 131,895 | 0.0% | 0.28% | +109.7% | |
CTMX | Cytomx Therapeutics, Inc. | $519,000 | -1.5% | 79,193 | 0.0% | 0.20% | +4.1% | |
TRVN | Trevena, Inc. | $500,000 | -28.5% | 233,850 | 0.0% | 0.20% | -24.7% | |
CSLT | Castlight Health, Inc. | $454,000 | +15.2% | 349,070 | 0.0% | 0.18% | +21.2% | |
XGN | Exagen, Inc. | $343,000 | +21.6% | 25,982 | 0.0% | 0.13% | +28.8% | |
EPZM | Epizyme, Inc. | $268,000 | -9.2% | 24,686 | 0.0% | 0.10% | -3.7% | |
NXTC | NextCure, Inc. | $109,000 | +23.9% | 10,044 | 0.0% | 0.04% | +30.3% | |
METC | Ramaco Resources, Inc. | $43,000 | -17.3% | 14,951 | 0.0% | 0.02% | -10.5% | |
HNRG | Hallador Energy Resources, Inc. | $21,000 | +133.3% | 14,270 | 0.0% | 0.01% | +166.7% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-02-16
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
Wayfair, Inc. | 25 | Q3 2023 | 83.5% |
Trevena, Inc. | 25 | Q4 2021 | 1.2% |
Finjan Holdings, Inc. | 23 | Q2 2020 | 18.5% |
Zuora, Inc. | 21 | Q3 2023 | 3.4% |
Evelo Biosciences, Inc. | 20 | Q1 2023 | 26.3% |
CytomX Therpeutics, Inc. | 19 | Q4 2021 | 2.3% |
LendingClub Corp. | 18 | Q3 2019 | 11.9% |
Rubius Therapeutics, Inc. | 18 | Q4 2022 | 21.4% |
Solarwinds Corp. | 17 | Q4 2022 | 60.4% |
Axcella Health, Inc. | 17 | Q2 2023 | 6.7% |
View HARBOURVEST PARTNERS LLC's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
SolarWinds Corp | February 14, 2022 | 3,719,600 | 2.3% |
N-able, Inc. | December 20, 2021 | 3,719,600 | 2.1% |
OncoMed Pharmaceuticals Inc | February 14, 2019 | 1,901,106 | 4.9% |
Wayfair Inc. | February 16, 2016 | 2,115,296 | 4.6% |
ENVIVIO INC | February 13, 2013 | 3,639,939 | 13.5% |
NETWORK ENGINES INCSold out | February 13, 2013 | 0 | 0.0% |
VOCALTEC COMMUNICATIONS LTD | August 06, 2010 | 243,689 | 2.1% |
CERAGON NETWORKS LTDSold out | July 26, 2007 | 0 | 0.0% |
VISTAPRINT LTDSold out | February 14, 2007 | 0 | 0.0% |
VOCALTEC COMMUNICATIONS LTD | May 26, 2006 | 1,218,444 | 24.4% |
View HARBOURVEST PARTNERS LLC's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
40-APP | 2024-04-24 |
13F-HR | 2024-02-14 |
13F-HR | 2023-11-14 |
13F-HR | 2023-08-14 |
13F-HR | 2023-05-15 |
13F-HR | 2023-02-14 |
13F-HR | 2022-11-14 |
13F-HR | 2022-08-15 |
13F-HR/A | 2022-05-26 |
13F-HR | 2022-05-13 |
View HARBOURVEST PARTNERS LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.